
A First-in-Human study of CT0590, a triple knock-out, allogeneic CAR T-cell therapy targeting BCMA and NKG2A, in patients with Relapsed/ Refractory Multiple Myeloma

C. Fu[1], L. Yan[1], W. Yao[1], J. Shang[1], S. Jin[1], S. Yan[1], F. Tang[1], Z. Zhu[1], D. Wu[1], Y. Li[2], N. Rajakumaraswamy[2], W. Zheng[2], H. Jiang[2], Z. Liao[2], and Z. Li[2]

[1] The First Affiliated Hospital of Soochow University, Suzhou, China

[2] CARsgen Therapeutics Co. Ltd., Shanghai, China.



To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CT0590 in a first-in-human (FIH), open-label, single center, phase I study in patients with relapsed refractory multiple myeloma (RRMM) (NCT05066022).

Eligibility: Age: 18-75 years; Treated with at least 3 prior regimens including at least one proteasome inhibitor (PI) and one immunomodulatory agent (IMiD) OR stable disease, relapse, or progression following treatment with at least one PI or one IMID; relapse within 12 months after the most recent therapy OR failed to achieve at least Minimal Response OR had progression within 60 days after the most recent therapy; an ECOG score 0-1.
Dose levels (i3+3 escalating scheme): 50×10^6, 150×10^6, 300×10^6, 450×10^6 CT0590 cells.

Corresponding author: Chengcheng Fu

Tel. +86 13962191404; **Email:** fuchengchengsz@163.com

RESULTS

Patient Characteristics and Outcomes55249.549 -93.7 72u

Preliminary results of this FIH study of CT0590, an allogeneic dual CAR T-cell therapy targeting BCMA and NKG2A for the treatment of RRMM and RRpPCL, demonstrate a manageable safety profile while achieving durable clinical responses. Additional clinical studies are warranted to further evaluate the clinical utility of CT0590.

This trial was funded in part by The National Natural Science Foundation of China (No. 82270210), the National Key Research and Development Program of China (No. 2023YFC3403700) and CARsgen Therapeutics Co., Ltd.2 C 7METHODSMC /P igure /MCID 52 >>64C q1.545157994823-1.4194313 0 0.00441 060.0441 0305.714 0